Business Wire

PUMA

4.11.2021 10:02:19 CET | Business Wire | Press release

Share
No Time for Waste: PUMA pilots testing for biodegradable RE:SUEDE version of its most iconic sneaker

Sports company PUMA has developed an experimental version of its most iconic sneaker, the SUEDE, to test for a product to make it biodegradable. By doing so, PUMA aims to meet the growing demand for sustainable products for a better future. The RE:SUEDE, which uses the latest technology available today, will be made from more sustainable materials such as Zeology tanned suede, biodegradable TPE and hemp fibres.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211104005105/en/

The RE:SUEDE experiment is a pilot in circularity, and today’s ultimate expression of the next generation SUEDE – with the ambition to set new standards of sustainability for the iconic shoe. Designed to help address the challenge of waste management in the footwear industry, the RE:SUEDE experiment will allow PUMA to take more responsibility when it comes to tackling the ‘after life’ of its products. The pilot will launch in January 2022, offering 500 selected participants in Germany the chance to join PUMA on its experimental journey towards circularity.

In partnership with PUMA, participants will wear their RE:SUEDEs for six months to test out the durability of a product using biodegradable materials in real life, before sending them back to PUMA via a take back infrastructure, designed to move the products to the next step in the experiment. The sneakers will then be subject to an industrial biodegradation process in a controlled environment at Valor Compostering B.V., owned by Ortessa Groep B.V., a family-run business of waste specialists in the Netherlands. The goal of this step is to determine if Grade A compost can be produced for agricultural use. The findings will help PUMA assess the biodegradable process and unpick essential research and development for the future of sustainable shoe consumption.

The RE:SUEDE experiment is the first circular programme to launch under PUMA’s “Circular Lab” – a new innovation hub, which is led by PUMA’s sustainability and design experts who work to develop the future of the company’s circularity programmes.

This pilot is a recharged, refreshed experiment in circularity, following PUMA’s exploration in the space in 2012, which saw the brand’s first attempt to create a biodegradable sneaker as part of its InCycle collection. Yet after four seasons, the sneaker was discontinued due to low demand and the need for further research and development.

Since 2012, PUMA’s innovation department has worked to address the technological limitations of the InCycle collection in order to apply such learnings into the RE:SUEDE experiment. Improvements include the use of new, innovative materials such as Zeology suede, which is made using a more sustainable tanning process and ensures better comfort for the wearer, when compared to other biodegradable materials evaluated at PUMA. The outsole of the RE:SUEDE has also been improved to ensure optimal wear.

“In 2012, our circular ambition was bold but the technology wasn’t quite there. As they say, with every challenge there’s an opportunity - and we’ve continued to push ourselves to do better by applying our strengths as well as acknowledging and improving on our weaknesses,” said Heiko Desens, PUMA’s Creative Director. “We hope that progress made during the RE:SUEDE experiment: ‘No Time For Waste‘ will help us continue to raise the bar in circularity testing – enabling our consumers to make better fashion choices in the future, so their sneakers can go ‘from Suede to Soil’, without compromising on product style or durability during ownership.”

About the partnership with Ortessa, Desens further comments: “We’re excited to partner with the experts at Ortessa, who share our passion in developing proactive and pragmatic solutions to the industry‘s waste problem. Their expertise is fundamental in helping us learn more about the after life of the RE:SUEDE, so we can continue moving forwards on our exploration of circularity.“

Rob Meulendijks, CEO of Ortessa comments: “As a family owned challenger in the waste industry, we pride ourselves in creating surprising innovations and fresh concepts to tackle real waste issues in a different and open way. There is a lot more we can all be doing to help tackle waste management, but taking on that challenge alone can be a difficult task for any brand. We are delighted to be working in partnership with PUMA on this special project, where we can apply our deep knowledge and insights on waste, use tried and controlled methods, to assess the biodegradability of the future, next-generation Suede.“

PUMA aims to share the results and insights gained from this experiment within the industry to achieve an even bigger impact when it comes to addressing the challenge of waste management in the footwear industry in general. Circularity is one of the pillars of PUMA’s FOREVER BETTER sustainability strategy. By 2025, PUMA aims to reduce waste by increasing the level of recycled polyester in its products to 75%, setting up product takeback schemes in its major markets and developing recycled material options for leather, rubber, cotton and polyurethane.

Since its first iteration in 1968, the PUMA SUEDE has been at the forefront of cultural turning points, transcending style and trends. With the RE:SUEDE, PUMA wants to give its consumers a stylish and more sustainable choice, while showcasing the latest technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye